Impaired Glucose Tolerance, Impaired Fasting Glucose and Cardiovascular Risk
To the Editor:
Tamita et al reported that abnormal glucose tolerance in patients with acute myocardial infarction (AMI) is a major risk factor for future cardiovascular events and might critically distinguish high-risk individuals. 1 The cardiovascular event-free survival rate in the impaired glucose tolerance (IGT) group and the group with newly diagnosed diabetes were 73% and 67%, respectively, at 5-year follow up. They combined these 2 groups as the abnormal glucose tolerance group and the event-free survival rate in the combined group was 70%, which was significantly lower than the rate (87%) in the normal glucose tolerance group. They pointed out the critical importance of oral glucose tolerance tests after AMI, because in their study, 81% of patients with newly-diagnosed abnormal glucose tolerance showed normal fasting plasma glucose concentrations defined as <110 mg/dl. However, the p-values of the hazard ratio for abnormal glucose tolerance and fasting plasma glucose were 0.0068 and 0.001, respectively, in their univariate Cox regression analysis. 1 Recently, the American Diabetes Association revised the cut point of impaired fasting glucose (IFG) as 100 mg/dl 2 and the International Diabetes Federation 3 and the American Heart Association 4 adopted this cut point. Therefore, they should evaluate not only IGT but also old and revised IFG as risk factors for future cardiovascular events as done by Kanaya et al. 5 I deeply appreciate if they would also study C-reactive protein (CRP) as a risk factor for future cardiovascular events as suggested by Matsushita et al in their cross-sectional study. 6 The optimal cut point of CRP might be 0.65 mg/L. 7, 8 
